A peptide that scientists long wrote off as harmless may deserve a second look in Alzheimer’s research. A 2026 commentary from a University of California, Santa Cruz biochemist argues that a small fragment called P3 can clump together faster than amyloid beta, the protein fragment at the center of Alzheimer’s research for decades.[1] It is an argument for more research, not a new treatment or a new way to lower your own risk.
What P3 is
Amyloid beta forms when enzymes cut a larger membrane protein, the amyloid precursor protein. Most drug development has aimed at the long, sticky version known as Abeta42. P3 comes from the same parent protein but through a different set of cuts. Because it was assumed to dissolve in water rather than pile up, it was largely left out of the research.
Jevgenij Raskatov, who studies amyloid peptides, says those assumptions were never properly tested. His lab has published three studies over five years reporting that P3 can form amyloid deposits at least as readily as amyloid beta, and that it does so more quickly. The lab also found evidence that P3 may be harmful to neurons, though less toxic than amyloid beta. He suggests renaming it “amyloid alpha.”
Why this matters
More than 400 clinical trials have tested Alzheimer’s drugs, most aimed at amyloid beta, and many have failed or helped only modestly. Antibody drugs that clear amyloid beta, such as lecanemab and donanemab, are now approved, but Raskatov argues the benefits so far remain limited. If P3 also plays a role, treatments that ignore it could be missing part of the picture.
What is still unknown
- This is a commentary that reviews earlier lab work. It is not a human trial.
- Researchers have not shown whether or how P3 contributes to the disease in patients. Raskatov himself says more research is needed.
- An independent group in the United Kingdom has reportedly confirmed and extended the findings, and other labs are beginning to study how P3 and amyloid beta interact. That work has yet to settle the question.
What you can do with this
Treat it as a reminder that Alzheimer’s science is still moving, and that no single peptide headline changes what you should do this week. If memory changes worry you, or a family history does, book a visit with your clinician and ask about an evaluation. Do not start, stop, or change a medication on your own.
At Bettering Me we follow the biology while keeping the habits with the strongest evidence in place: regular strength and aerobic exercise, steady sleep, and managing blood pressure and blood sugar with your care team. This commentary does not change that list. It only suggests the research field may be wider than we thought.
References
[1] Raskatov JA. Amyloid Alpha: The Neglected Cousin of Amyloid Beta. ChemBioChem, 2026;27:e202500912. Commentary. DOI: https://doi.org/10.1002/cbic.202500912. Finding as used: the P3 peptide (proposed name amyloid alpha) can form aggregates and fibrils, may interact with amyloid beta, and may be neurotoxic; further research is needed. Reported by ScienceDaily, October 14, 2026. ↑︎
Kurt Greiner
Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.
Leave a Reply